MaaT Pharma

OverviewSuggest Edit

MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.
TypePrivate
Founded2014
HQLyon, FR
Websitemaatpharma.com

Latest Updates

Employees (est.) (May 2020)26(-3%)

Key People/Management at MaaT Pharma

Herve Affagard

Herve Affagard

Chief Executive Officer – Co Founder
Ronald Carter

Ronald Carter

Chief Medical Officer
Siân Crouzet

Siân Crouzet

Chief Operations Officer
Jean-Marc Renard

Jean-Marc Renard

Chief Business Officer
Eric de la Fortelle

Eric de la Fortelle

Non-Executive Director
Julien Samson

Julien Samson

Independent Non-Executive Director
Show more

MaaT Pharma Office Locations

MaaT Pharma has offices in Lyon and Lyon-7E-Arrondissement
Lyon, FR (HQ)
69 Avenue Jean Jaurès
Lyon-7E-Arrondissement, FR (HQ)
317 Avenue Jean Jaurès
Show all (2)

MaaT Pharma Financials and Metrics

Summary Metrics

Founding Date

2014

MaaT Pharma total Funding

$32.1 m

MaaT Pharma latest funding size

$19.81 m

Time since last funding

4 months ago

MaaT Pharma investors

MaaT Pharma's latest funding round in February 2020 was reported to be $19.8 m. In total, MaaT Pharma has raised $32.1 m
Show all financial metrics

MaaT Pharma Online and Social Media Presence

Embed Graph

MaaT Pharma Blogs

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

The post MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics appeared first on MaaT Pharma.

Statement following recently FDA reported event with FMT in USA

The post Statement following recently FDA reported event with FMT in USA appeared first on MaaT Pharma.

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

The post MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform appeared first on MaaT Pharma.

IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal

The post IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal appeared first on MaaT Pharma.

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

The post MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD appeared first on MaaT Pharma.

MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

The post MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD appeared first on MaaT Pharma.
Show more

MaaT Pharma Frequently Asked Questions

  • When was MaaT Pharma founded?

    MaaT Pharma was founded in 2014.

  • Who are MaaT Pharma key executives?

    MaaT Pharma's key executives are Herve Affagard, Ronald Carter and Siân Crouzet.

  • How many employees does MaaT Pharma have?

    MaaT Pharma has 26 employees.

  • Who are MaaT Pharma competitors?

    Competitors of MaaT Pharma include FaHRAS, Hello Heart and Oura.

  • Where is MaaT Pharma headquarters?

    MaaT Pharma headquarters is located at 69 Avenue Jean Jaurès, Lyon.

  • Where are MaaT Pharma offices?

    MaaT Pharma has offices in Lyon and Lyon-7E-Arrondissement.

  • How many offices does MaaT Pharma have?

    MaaT Pharma has 2 offices.